Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

V Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

Non-GAAP Financial Measures This press release provides financial measures for net revenue, cost of sales, gross margin, net loss and basic and diluted loss per share that exclude specifically identified non-routine items, and are therefore not calculated in accordance with accounting principles generally accepted in the United States ("GAAP"). Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance that enhances management's and investors' ability to evaluate and compare Cadence's operating results.

These non-GAAP financial measures are not intended to be used in isolation and should not be considered a substitute for any other performance measure determined in accordance with GAAP. Investors and potential investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool, including that other companies may calculate similar non-GAAP financial measures differently than Cadence, limiting their usefulness as a comparative tool. Cadence compensates for these limitations by providing specific information regarding the GAAP amount excluded from the non-GAAP financial measures. Cadence further compensates for the limitations of its use of non-GAAP financial measures by presenting comparable GAAP measures more prominently. Investors and potential investors are encouraged to review the calculation of non-GAAP financial measures contained within this press release with Cadence's GAAP net income and basic and diluted loss per share.

About Cadence Pharmaceuticals, Inc.Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 iLab Solutions, the global ... of Siri Bryant as the new Director of Institutional ... Core Implementations. These two new leadership positions were created ... by ensuring that iLab continues to meet the needs ... four years, iLab has been deployed at over 450 ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
(Date:12/17/2014)... December 16, 2014 The Activated ... 2013, which is why IBISWorld updated its original industry ... to benefit from an intensified focus on environmental policy. ... new emission standards for power plants and a range ... to IBISWorld Industry Analyst Sarah Kahn, “a range of ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... are being held to solicit public sentiment on Assembly ... 45 . The bills were introduced to the state legislature ... and parthenogenesis (the process of manipulating the genetic material of ... material from any other cell, in a way that causes ...
... just go bad. Not so often, components that supply power ... case beginning at 11:57 p.m. Monday night with TDS Internet ... and downed dial-up and DSL users en masse, TDS Telecom ... restored at 2:40 a.m. to all users. , ,TDS Internet ...
... determined to give heavy email users something they lack: time and ... a heavy email user, talks about the inspiration for his company, ... world. , , WTN: How much email do you get everyday? ... messages a day from various email accounts with about 70% of ...
Cached Biology Technology:Public Hearing Held for controversial anti-cloning bills 2Public Hearing Held for controversial anti-cloning bills 3Public Hearing Held for controversial anti-cloning bills 4TDS Suffers 29-State System Outage 2TDS Suffers 29-State System Outage 3WTN Interview: Alex Bratton: EmailRX's founder on viruses and spam 2WTN Interview: Alex Bratton: EmailRX's founder on viruses and spam 3
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/10/2014)... 2014     ...   Jifflenow, a leading ... for business-to-business (B2B) events, today announced a partnership ... near-field communication (NFC), Bluetooth low energy (BLE), and ... , Jifflenow will integrate its meeting ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... BOULDER, Colo., September 11, 2012 BiOptix announced continued support ... in BioWest 2012, a leading life sciences showcase ... City Center. "BiOptix continues to believe in the ... Association, noted Rick Whitcomb, President and CEO of ...
... screening technique developed by researchers at the RIKEN Plant ... novel immune-priming compounds in Arabidopsis plants. Discovery ... plant growth or crop yield, establishes the new technique ... crops from damaging pathogens. Plant activators, compounds that ...
... Mich.A strip of glass covered in hairy nanoparticles can ... system, and other toxic metals in fluids. ... Northwestern University and the University of Michigan found that ... common form of mercury pollution, at unprecedentedly small concentrations. ...
Cached Biology News:BiOptix Participates in Leading Life Sciences Event BioWest 2012 2Screening technique uncovers 5 new plant activator compounds 2Measuring mercury levels: Nano-velcro detects water-borne toxic metals 2Measuring mercury levels: Nano-velcro detects water-borne toxic metals 3
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
PFM8 Antibody...
Biology Products: